216 related articles for article (PubMed ID: 18535026)
1. Relapses in multiple sclerosis are age- and time-dependent.
Tremlett H; Zhao Y; Joseph J; Devonshire V;
J Neurol Neurosurg Psychiatry; 2008 Dec; 79(12):1368-74. PubMed ID: 18535026
[TBL] [Abstract][Full Text] [Related]
2. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis.
Gorman MP; Healy BC; Polgar-Turcsanyi M; Chitnis T
Arch Neurol; 2009 Jan; 66(1):54-9. PubMed ID: 19139299
[TBL] [Abstract][Full Text] [Related]
3. Early relapses, onset of progression, and late outcome in multiple sclerosis.
Scalfari A; Neuhaus A; Daumer M; Deluca GC; Muraro PA; Ebers GC
JAMA Neurol; 2013 Feb; 70(2):214-22. PubMed ID: 23407713
[TBL] [Abstract][Full Text] [Related]
4. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.
Scalfari A; Neuhaus A; Degenhardt A; Rice GP; Muraro PA; Daumer M; Ebers GC
Brain; 2010 Jul; 133(Pt 7):1914-29. PubMed ID: 20534650
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of clinical characteristics for 'benign' multiple sclerosis.
Ramsaransing GS; De Keyser J
Eur J Neurol; 2007 Aug; 14(8):885-9. PubMed ID: 17662009
[TBL] [Abstract][Full Text] [Related]
6. Predictors of relapse rate in MS clinical trials.
Held U; Heigenhauser L; Shang C; Kappos L; Polman C;
Neurology; 2005 Dec; 65(11):1769-73. PubMed ID: 16344520
[TBL] [Abstract][Full Text] [Related]
7. Clinical predictors of disease progression in multiple sclerosis patients with relapsing onset in a nation-wide cohort.
Alroughani RA; Akhtar S; Ahmed SF; Al-Hashel JY
Int J Neurosci; 2015; 125(11):831-7. PubMed ID: 25329929
[TBL] [Abstract][Full Text] [Related]
8. Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis.
Novotna M; Paz Soldán MM; Abou Zeid N; Kale N; Tutuncu M; Crusan DJ; Atkinson EJ; Siva A; Keegan BM; Pirko I; Pittock SJ; Lucchinetti CF; Noseworthy JH; Weinshenker BG; Rodriguez M; Kantarci OH
Neurology; 2015 Aug; 85(8):722-9. PubMed ID: 26208962
[TBL] [Abstract][Full Text] [Related]
9. Using observational analysis of multiple sclerosis relapse to design outcomes-based contracts for disease-modifying drugs: a feasibility assessment.
Lage MJ; Carroll CA; Fairman KA
J Med Econ; 2013 Sep; 16(9):1146-53. PubMed ID: 23844620
[TBL] [Abstract][Full Text] [Related]
10. Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis.
Moccia M; Palladino R; Carotenuto A; Russo CV; Triassi M; Lanzillo R; Brescia Morra V
Mult Scler Relat Disord; 2016 Nov; 10():90-96. PubMed ID: 27919507
[TBL] [Abstract][Full Text] [Related]
11. Ten-year prognosis in multiple sclerosis: a better outcome in relapsing-remitting patients but not in primary progressive patients.
Kerbrat A; Hamonic S; Leray E; Tron I; Edan G; Yaouanq J;
Eur J Neurol; 2015 Mar; 22(3):507-e35. PubMed ID: 25515927
[TBL] [Abstract][Full Text] [Related]
12. Natural history of multiple sclerosis: a unifying concept.
Confavreux C; Vukusic S
Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
[TBL] [Abstract][Full Text] [Related]
13. Multiple sclerosis relapses: a multivariable analysis of residual disability determinants.
Vercellino M; Romagnolo A; Mattioda A; Masera S; Piacentino C; Merola A; Chiò A; Mutani R; Cavalla P
Acta Neurol Scand; 2009 Feb; 119(2):126-30. PubMed ID: 18684216
[TBL] [Abstract][Full Text] [Related]
14. Sex as a determinant of relapse incidence and progressive course of multiple sclerosis.
Kalincik T; Vivek V; Jokubaitis V; Lechner-Scott J; Trojano M; Izquierdo G; Lugaresi A; Grand'maison F; Hupperts R; Oreja-Guevara C; Bergamaschi R; Iuliano G; Alroughani R; Van Pesch V; Amato MP; Slee M; Verheul F; Fernandez-Bolanos R; Fiol M; Spitaleri DL; Cristiano E; Gray O; Cabrera-Gomez JA; Shaygannejad V; Herbert J; Vucic S; Needham M; Petkovska-Boskova T; Sirbu CA; Duquette P; Girard M; Grammond P; Boz C; Giuliani G; Rio ME; Barnett M; Flechter S; Moore F; Singhal B; Bacile EA; Saladino ML; Shaw C; Skromne E; Poehlau D; Vella N; Spelman T; Liew D; Kilpatrick TJ; Butzkueven H;
Brain; 2013 Dec; 136(Pt 12):3609-17. PubMed ID: 24142147
[TBL] [Abstract][Full Text] [Related]
15. Anti-HHV-6 IgG titer significantly predicts subsequent relapse risk in multiple sclerosis.
Simpson S; Taylor B; Dwyer DE; Taylor J; Blizzard L; Ponsonby AL; Pittas F; Dwyer T; van der Mei I
Mult Scler; 2012 Jun; 18(6):799-806. PubMed ID: 22084489
[TBL] [Abstract][Full Text] [Related]
16. Seasonal patterns of relapse and disability in Danish MS patients: A population-based cohort study.
Elser HC; Koch-Henriksen N; Magyari M
Mult Scler Relat Disord; 2021 Apr; 49():102739. PubMed ID: 33450501
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
[TBL] [Abstract][Full Text] [Related]
18. Specific clinical phenotypes in relapsing multiple sclerosis: The impact of relapses on long-term outcomes.
Scott TF; Gettings EJ; Hackett CT; Schramke CJ
Mult Scler Relat Disord; 2016 Jan; 5():1-6. PubMed ID: 26856936
[TBL] [Abstract][Full Text] [Related]
19. Monthly ambient sunlight, infections and relapse rates in multiple sclerosis.
Tremlett H; van der Mei IA; Pittas F; Blizzard L; Paley G; Mesaros D; Woodbaker R; Nunez M; Dwyer T; Taylor BV; Ponsonby AL
Neuroepidemiology; 2008; 31(4):271-9. PubMed ID: 18971584
[TBL] [Abstract][Full Text] [Related]
20. Comorbidity increases the risk of relapse in multiple sclerosis: A prospective study.
Kowalec K; McKay KA; Patten SB; Fisk JD; Evans C; Tremlett H; Marrie RA;
Neurology; 2017 Dec; 89(24):2455-2461. PubMed ID: 29117961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
